| Combination of | |
|---|---|
| Indacaterol | Beta-2 adrenergic receptor agonist |
| Mometasone | Corticosteroid |
| Clinical data | |
| Trade names | Atectura Breezhaler, Bemrist Breezhaler |
| Other names | QMF149, IND/MF |
| License data | |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Indacaterol/mometasone, sold under the brand name Atectura Breezhaler among others, is a fixed-dose combination medication for the treatment of asthma in adults and adolescents twelve years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2 agonists.[2]
The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat).[2] Other common side effects include upper respiratory tract infection (nose and throat infections) and headache.[2] Indacaterol/mometasone was approved for medical use in the European Union in May 2020,[2] and in Japan in June 2020.[6]
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Adrenergics, inhalants |
| ||||||||
| Glucocorticoids |
| ||||||||
| Anticholinergics/ muscarinic antagonist |
| ||||||||
| Mast cell stabilizers |
| ||||||||
| Xanthines |
| ||||||||
| Eicosanoid inhibition |
| ||||||||
| Others/unknown |
| ||||||||
| Combination products |
| ||||||||
| |||||||||
|
| |||||
|---|---|---|---|---|---|
| Glucocorticoids |
| ||||
| Antiglucocorticoids |
| ||||
| Synthesis modifiers |
| ||||
| |||||
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|
| GRTooltip Glucocorticoid receptor |
| ||||||||
| |||||||||
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
